Eirion Therapeutics, Inc.

Rise in prevalence of diseases such as axillary hyperhidrosis in developed countries, expanding product launches and product approvals, and surge in demand. WILMINGTON, DE, UNITED STATES, September 24, 2025 / EINPresswire.com / -- Allied Market Research published a report, titled, " Hyperhidrosis Treatment Market by Type (Axillary hyperhidrosis, Palmar hyperhidrosis, Plantar hyperhidrosis, Others), by Treatment (Botulinum toxin injections, Topical treatment, Oral medication), by Age (Below 50 years, Above 50 years): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global hyperhidrosis treatment industry generated $575.3 million in 2021, and is projected to reach $950.7 million by 2031, manifesting a CAGR of 5.1% from 2022 to 2031. Prime determinants of growth - Rise in prevalence of diseases such as axillary hyperhidrosis in developed countries, expanding product launches and product approvals, and surge in demand for improved healthcare services drive the growth of the global hyperhidrosis treatment market. However, lack of awareness and unfavorable reimbursement scenario restrain the market growth. On the other hand, rise in utilization topical treatment and technological advancements present new opportunities in the coming years. Download Sample Report - https://www.alliedmarketresearch.com/request-sample/17972 Covid-19 Scenario The Covid-19 pandemic made a negative impact on the growth of the global hyperhidrosis treatment market. Hospitals either canceled or postponed the hyperhidrosis treatment due to shift in resources toward taking care of Covid-infected patients. However, during the pandemic, many patients carried out treatments on their illnesses using self-medication or other unconventional methods. Patients suffering from hyperhidrosis had a disproportionately larger rate of depression during the Covid-19 pandemic, particularly the female patients. In addition, some of these patients faced difficulties in receiving the therapy during the pandemic. The axillary hyperhidrosis segment to maintain its lead position during the forecast period Based on type, the axillary hyperhidrosis segment accounted for the highest market share in 2021, contributing to around three-fifths of the global hyperhidrosis treatment market, and is projected to maintain its lead position during the forecast period. Moreover, this segment is projected to manifest the largest CAGR of 5.4% from 2022 to 2031. This is due to high incidence of axillary hyperhidrosis among younger as well as adult generation. The report also analyzes the segments including palmar hyperhidrosis, plantar hyperhidrosis, and others. The topical treatment segment to continue its dominant share throughout the forecast period Based on treatment, the topical treatment segment contributed to the highest market share in 2021, accounting for more than three-fifths of the global hyperhidrosis treatment market, and is projected to continue its dominant share throughout the forecast period. Moreover, this segment is estimated to manifest the highest CAGR of 5.4% from 2022 to 2031. This is attributed to product innovation and effective & rapid effects of the topicals. The report also analyzes the segments including botulinum toxin injections and oral medication. The below 50 years segment to continue its highest contribution throughout the forecast period Based on age, the below 50 years segment accounted for the largest market share in 2021, holding around three-fifths of the global hyperhidrosis treatment market, and is estimated to continue its highest contribution throughout the forecast period. In addition, this segment is projected to register the fastest CAGR of 5.3% from 2022 to 2031. This is due to high incidence of hyperhidrosis disease in below 50-year age group. The report also analyzes the above 50 years segment. For Purchase Inquiry - https://www.alliedmarketresearch.com/purchase-enquiry/17972 North America to maintain its leadership status throughout the forecast period Based on region, North America held the largest market share in 2021, accounting for more than two-fifths of the global hyperhidrosis treatment market, and will maintain its leadership status throughout the forecast period. This is attributed to technological advancements in hyperhidrosis treatment, high incidence of disease, presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is expected to grow at the largest CAGR of 5.9% from 2022 to 2031, owing to development of healthcare infrastructure and increase in investments projects in the region. Leading Market Players AbbVie Inc. Avanor Healthcare Ltd. Brickbell Biotech, Inc. Dr August Wolff GmbH & Co. Kg Drugs Dr. Reddy's Laboratories Ltd. Eirion Therapeutics, Inc. Eli Lilly and Company Hugel, Inc. Kaken Pharmaceutical Co., Ltd. Intas Pharmaceuticals Ltd. Roivant Sciences Ltd. Theravida, Inc. The report analyzes these key players and highlights various strategies such as new product launches, partnerships, expansion, and others to raise their market penetration and strengthen their position in the market. The report offers a detailed analysis that outlines product portfolio, operating segments, business performance, and key developments of each market player. Similar Research Reports for Information, Communication and Technology: Human Chorionic Gonadotropin (HCG) Market - https://www.alliedmarketresearch.com/human-chorionic-gonadotropin-HCG-market U.S. Intraoperative Neuromonitoring Market - https://www.alliedmarketresearch.com/us-intraoperative-neuromonitoring-market Scaffold Technology Market - https://www.alliedmarketresearch.com/scaffold-technology-market-A11103 Cardiovascular Prosthetic Devices Market - https://www.alliedmarketresearch.com/cardiovascular-prosthetic-devices-market Endotherapy Devices Market - https://www.alliedmarketresearch.com/endotherapy-devices-market About Us - Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Pawan Kumar, the CEO of Allied Market Research is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. David Correa Allied Market Research + + + +1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

A roundup of the most newsworthy healthcare press releases from PR Newswire, including Zimmer Biomet's acquisition of Paragon 28, Icy Hot's partnership with Unrivaled and three major health news trends from January. NEW YORK, Feb. 7, 2025 /PRNewswire/ -- With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most popular releases and newsworthy trends, here's a recap of some of the past month's most read- and engaged-with stories. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Monthly Health Press Release Roundup, January 2025. Photos provided by Icy Hot, March of Dimes Inc. and BD (Becton, Dickinson and Company). Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 "This proposed transaction further diversifies Zimmer Biomet's portfolio outside of core orthopedics and positions us well in one of the highest growth specialized segments in musculoskeletal care…," said Ivan Tornos, President and Chief Executive Officer of Zimmer Biomet. Icy Hot Signs on as Official Recovery Partner of Unrivaled Icy Hot will serve as the Official Recovery Partner of the groundbreaking professional women's basketball league. Icy Hot will provide topical pain relief products to players during games and practice sessions, and in recovery and training facilities throughout the nine-week season. AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology "We are excited to collaborate with Neomorph to develop novel molecular glue degraders which could pave the way for new, effective therapies in the treatment of immune disorders and cancer," said Steven Elmore, vice president, small molecule therapeutics and platform technologies at AbbVie. Michael J. Fox Honored with Presidential Medal of Freedom The nation's highest civilian honor recognizes his tireless advocacy and dedication to speeding a cure for Parkinson's disease. "I'm grateful for this recognition, which I share with the patients, families and researchers who have brought us closer than ever to ending Parkinson's disease once and for all," said Fox. Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors iPSC-derived cell therapies have the potential to transform cancer care by offering scalable, 'off-the-shelf' treatment options. The companies aim to accelerate the development of more potent and durable cell therapies while maintaining manufacturability at scale. Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results "We believe that ET-02 has the potential to not only treat but prevent androgenic alopecia. The results of this clinical trial show we are an important step closer to potentially having a solution for hair loss," said Jon Edelson, MD, CEO and President of Eirion. Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk to Discover Novel Targets for Metabolic Disease "Metabolic disease - including obesity - affects people all over the world, yet newer targets with genetic evidence are primarily based on studies with European-ancestry populations. As a result, there is still an unmet need in this space," said David Moller, Chief Scientific Officer at Variant Bio. Panasonic Well Sets the Stage for the Future of Family Wellness in Opening Keynote at CES 2025 Families are at their breaking point as chronic stress, disconnection, and fragmented wellness solutions are taking a toll, and the call for help is loud and clear. To confront the mounting wellness imperatives families face in their daily lives, Panasonic Well CEO Yoky Matsuoka, took the stage to introduce the next step in building a comprehensive wellness ecosystem to support families. SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression This approval, which was granted following FDA Priority Review, is supported by positive results from the randomized, double-blind, multicenter, placebo-controlled study in which SPRAVATO® alone showed a rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours. GORTEC Announces New Trial Success for Head and Neck Cancer Treatment "This is the first time in decades where a therapy demonstrated superiority over standard of care cisplatin-radiotherapy in high-risk patients with [locally advanced squamous cell carcinoma of head and neck] LA-SCCHN," said Prof Jean Bourhis, Principal Investigator of the study and Medical Director of the GORTEC. Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity Company announced the initiation of a 13-week study to evaluate the safety and efficacy of oral VK2735 dosed once daily. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc. The acquisition is expected to further Boston Scientific's strategy to address coronary and peripheral disease. "Bolt Medical is developing a next-generation technology that is highly complementary to our existing portfolio. The addition of this system to our offerings can help us better serve physicians and their patients," said Lance Bates, senior vice president and president, Interventional Cardiology Therapies, Boston Scientific. FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Ongoing treatment can slow disease progression and prolong the benefit of therapy, with the goal of helping patients maintain who they are for longer. For maintenance treatment, once every four weeks dosing regimen may be easier than once every two weeks dosing for patients and care partners to continue treatment for early Alzheimer's Disease. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Trending Topics Among the health news that was distributed in January, the PR Newswire team was able to spot several larger stories that highlight the trends shaping the industry. Cervical Cancer Awareness Month: January saw an increased focus on women's health, with our team noting a surge in new medical guidelines and concerning research findings. The American Cancer Society released data showing cancer mortality continues to decline despite rising incidence in women. New ASCCP guidelines introduced more precise screening methods, while survey results revealed many women are skipping critical OB-GYN exams - highlighting ongoing challenges in cervical cancer prevention and detection. Maternal Health Awareness Day: The maternal health crisis generated significant wire activity surrounding Maternal Health Awareness Day, which was observed on Jan. 23. March of Dimes celebrated historical White House engagement on the issue and healthcare providers shared promising results from innovative programs, including MedStar Health's Safe Babies Safe Moms initiative and Preeclampsia Foundation's creative intervention targeting Black maternal health. California Wildfires Response: As wildfires devastated the Los Angeles area, PR Newswire distributed a wave of announcements as organizations across sectors mobilized support for affected communities. Healthcare providers like CVS Health, DaVita and Magellan Health ensured continued care and crisis support. Fitness chains including 24 Hour Fitness and Crunch opened their facilities to displaced residents. Specialized assistance came from organizations like Braille Institute supporting visually impaired individuals, while companies donated air purifiers and other relief supplies to vulnerable populations. All news releases related to severe storms and extreme weather events across the U.S. can be found here. Looking ahead: PR Newswire anticipates significant wire activity in February around American Heart Month, with releases spotlighting cardiovascular health innovations and awareness campaigns. Early February announcements are expected to focus on cancer research breakthroughs around World Cancer Day (Feb. 4), while health equity themes will likely dominate coverage of National Black HIV/AIDS Awareness Day (Feb. 7). Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Demonstrates Potential for ET-02 to be Significantly More Effective Than Existing Treatments for Hair Loss WOBURN, Mass., Jan. 8, 2025 /PRNewswire/ -- Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, announced today the successful results of its first-in-man clinical trial for the treatment of androgenic alopecia (age-related hair loss) using its topical pharmaceutical ET-02. Jon Edelson, MD, CEO and President of Eirion, commented "80 million people in the United States suffer from hair loss and there is no truly effective treatment for this condition today. Because of ET-02's unique mechanism of action, we believe that ET-02 has the potential to not only treat but prevent androgenic alopecia. The results of this clinical trial show we are an important step closer to potentially having a solution for hair loss." In a double-blind, placebo-controlled, dose-ranging clinical study of 24 subjects at three U.S. investigational sites, three equal-sized groups were treated once daily for 4 weeks with either a control treatment comprised of the product vehicle, a 1.25% solution of ET-02 or a 5% solution of ET-02. A final assessment of the subjects was made one week after the treatments ended. Key results of the study showed: Safety: ET-02 was found to be safe and well tolerated. Dose-Response: A dose-response effect was observed, with minimal response observed in the vehicle and 1.25% ET-02 groups compared to the significant response observed in the higher dose 5% ET-02 group. Thus, for analysis, the placebo group was the combined vehicle and 1.25% ET-02 dose groups. Hair Growth: 5% ET-02 resulted in a 6-fold increase in non-vellus (or normal) hair count compared to the placebo group at the end of the fifth week of the study. For comparative purposes, after one month of treatment 5% ET-02 demonstrated more non-vellus hair growth than topical minoxidil produced after 4 months of treatment as measured in a separate clinical trial of minoxidil (N=180), the current "gold standard" treatment for androgenic alopecia. Hair Width: 5% ET-02 resulted in an approximately ten percentage point improvement in non-vellus hair width over the placebo group, which was essentially unchanged. Eirion's first-in-man study results confirm the efficacy of 5% ET-02 as demonstrated in a previous controlled pre-clinical study of topical 5% ET-02 treating 60 human scalp tissue grafts from men with androgenic alopecia. In that study, ET-02 was markedly more effective than the control group. The net rate of hair growth produced by ET-02 in the fourth month of treatment was four times greater than the amount produced by minoxidil in a second, separate pre-clinical study (N=103) using the same experimental graft model. Eirion plans to begin a Phase 2 clinical trial (N≈150) in 2025 with a 6-month treatment period with the goal of confirming ET-02's safety and efficacy. Jerry Shapiro, MD, a leading expert on the treatment of hair loss and Professor of Dermatology at New York University Grossman School of Medicine noted that "Eirion's clinical trial results are clear-cut and remarkable. Achieving this amount of hair growth in just 5 weeks in a clinical trial is unprecedented. ET-02 represents a potentially substantial advancement over minoxidil and other commercially available pharmaceuticals for patients struggling with hair loss, not only from an efficacy standpoint, but also from safety and ease-of-use standpoints. Due to its non-hormonal mechanism of action, ET-02 is not expected to have the same side effects that patients complain of, like sexual dysfunction, for androgen inhibition treatments like finasteride. ET-02 is being tested as a once-a-day treatment, rather than the less convenient twice-a-day regimen required for topical minoxidil." Dr Shapiro added, "I look forward to future clinical studies of ET-02." ET-02 has a novel mechanism of action which restores normal function to hair follicle stem cells that have become inactive in age-related hair loss due to a defect that develops in the stem cell biology. Hair follicle stem cells are known to be the "master control switches" for hair growth. By correcting this defect and returning the stem cells to normal activity and function, the expectation is that hair growth can be restored. Eirion expects ET-02 has the potential to be significantly more effective than existing treatments since it directly addresses what Eirion believes is the fundamental cause of androgenic alopecia, while existing treatments do not. Eirion also believes ET-02 has the potential to treat and prevent hair greying by impacting in a similar manner the melanocyte stem cells which control the production of hair color. Eirion Therapeutics will participate in the Aesthetics Tech Forum taking place January 9 – 10, 2025, in Newport Beach, California. Dr Edelson will present an update on Eirion and clinical trial results during the conference session "Company Presentations" that will take place on Thursday January 9th 1:25 PM – 2:30 PM PST. About Eirion Therapeutics, Inc. Eirion Therapeutics, Inc. is a privately held, clinical stage biopharmaceutical company that is developing next-generation prescription products for aesthetic medicine. Eirion currently has a rich pipeline of product candidates focusing on treatments for wrinkles, androgenic alopecia, hair greying and primary axillary hyperhidrosis. Eirion's product candidates, all of which have been studied in one or more clinical trials, include AI-09 liquid injectable neuromodulator, ET-01 topical neuromodulator, and ET-02 topical small molecule. To learn more about Eirion, please visit: Media Contact Megan Driscoll EvolveMKD [email protected] SOURCE Eirion Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED